Cancer/testis antigens

ISA Pharmaceuticals and Cancer Focus Fund Announce $5 Million Investment to Support First-in-Human Trial of ISA's Novel Immunotherapy ISA103 in Uveal Melanoma

Retrieved on: 
Wednesday, January 4, 2023
Human, MD Anderson Cancer Center, Hepatitis, ISA, Immunotherapy, Patient, HPV16, HLA, PRAME, Neoplasm, Epitope, Cell, CD8, Palestinian National Interest Committee, Immune system, Antigen, Preferential hyperacuity perimetry, Fund, Disease, University, B.V, Associate, Uveal melanoma, Breast, Central tolerance, Global Monitoring Plan, Safety, Clinical trial, Anderson, Pancreatic serous cystadenoma, Regeneron Pharmaceuticals, LSU, Infection, CD4, Principal, Cancer, Monroe Dunaway Anderson, Children's Art Project at The University of Texas MD Anderson Cancer Center, Investment, Lung, Research, Cancer/testis antigens, LP, Neuroblastoma, Pharmaceutical industry, Vaccine, Melanoma

OEGSTGEEST, Netherlands and HOUSTON, Jan. 4, 2023 /PRNewswire/ -- ISA Pharmaceuticals, B.V., a clinical stage biotech company developing immunotherapies to treat cancers and infectious diseases, and Cancer Focus Fund, LP, a unique investment fund established in collaboration with The University of Texas MD Anderson Cancer Center to provide funding and clinical expertise to advance promising cancer therapies, today announced that Cancer Focus Fund is investing $5 million in funding to support ISA103, ISA's PRAME-targeting immunotherapy, in a first-in-human study for the treatment of uveal melanoma, a rare ocular cancer.

Key Points: 
  • ISA103 immunotherapy targets PRAME (PReferentially expressed Antigen in MElanoma), a cancer testis antigen that is overexpressed in various solid and liquid cancers.
  • We believe this investment from the Cancer Focus Fund and the clinical expertise provided by MD Anderson will significantly advance ISA103 as an immunotherapy with the potential to combat this rare but debilitating malignancy."
  • "Cancer Focus Fund is committed to using its investments to support the clinical development of truly innovative cancer therapies," said Ross Barrett, a founder and Managing Partner of Cancer Focus Fund.
  • The Cancer Focus Fund LP is a unique investment fund established in collaboration with The University of Texas MD Anderson Cancer Center.

ISA Pharmaceuticals and Cancer Focus Fund Announce $5 Million Investment to Support First-in-Human Trial of ISA's Novel Immunotherapy ISA103 in Uveal Melanoma

Retrieved on: 
Wednesday, January 4, 2023
Human, MD Anderson Cancer Center, Hepatitis, ISA, Immunotherapy, Patient, HPV16, HLA, PRAME, Neoplasm, Epitope, Cell, CD8, Palestinian National Interest Committee, Immune system, Antigen, Preferential hyperacuity perimetry, Fund, Disease, University, B.V, Associate, Uveal melanoma, Breast, Central tolerance, Global Monitoring Plan, Safety, Clinical trial, Anderson, Pancreatic serous cystadenoma, Regeneron Pharmaceuticals, LSU, Infection, CD4, Principal, Cancer, Monroe Dunaway Anderson, Children's Art Project at The University of Texas MD Anderson Cancer Center, Investment, Lung, Research, Cancer/testis antigens, LP, Neuroblastoma, Pharmaceutical industry, Vaccine, Melanoma

OEGSTGEEST, Netherlands and HOUSTON, Jan. 4, 2023 /PRNewswire/ -- ISA Pharmaceuticals, B.V., a clinical stage biotech company developing immunotherapies to treat cancers and infectious diseases, and Cancer Focus Fund, LP, a unique investment fund established in collaboration with The University of Texas MD Anderson Cancer Center to provide funding and clinical expertise to advance promising cancer therapies, today announced that Cancer Focus Fund is investing $5 million in funding to support ISA103, ISA's PRAME-targeting immunotherapy, in a first-in-human study for the treatment of uveal melanoma, a rare ocular cancer.

Key Points: 
  • ISA103 immunotherapy targets PRAME (PReferentially expressed Antigen in MElanoma), a cancer testis antigen that is overexpressed in various solid and liquid cancers.
  • We believe this investment from the Cancer Focus Fund and the clinical expertise provided by MD Anderson will significantly advance ISA103 as an immunotherapy with the potential to combat this rare but debilitating malignancy."
  • "Cancer Focus Fund is committed to using its investments to support the clinical development of truly innovative cancer therapies," said Ross Barrett, a founder and Managing Partner of Cancer Focus Fund.
  • The Cancer Focus Fund LP is a unique investment fund established in collaboration with The University of Texas MD Anderson Cancer Center.

T-knife Therapeutics Announces Dosing of First Patient with TK-8001 in the IMAG1NE Phase 1/2 Clinical Trial

Retrieved on: 
Thursday, October 20, 2022
SAN, TCR, Trust, Therapy, Neoplasm, Patient, Cancer/testis antigens, Human, MYT, Cancer, Technology, Mouse, Blood, Molecular medicine, Safety, Testicle, GLOBE, Hlas, Clinical trial, MAGE-A1, Berlin, Max, Genetic engineering, Antigen, HLA, Primary tumor, Pharmaceutical industry, Medical imaging, Vaccine

We are excited to bring our first MyT Platform derived product candidate into the clinic, added Thomas M. Soloway, Chief Executive Officer of T-knife.

Key Points: 
  • We are excited to bring our first MyT Platform derived product candidate into the clinic, added Thomas M. Soloway, Chief Executive Officer of T-knife.
  • The IMAG1NE Phase 1/2 trial is an accelerated dose-titration, open-label, multi-center Phase 1/2 trial designed to evaluate the safety and preliminary efficacy of TK-8001 in patients with MAGE-A1 positive solid tumors.
  • The Phase 1 part of the study is focused on the selection of a dose to advance into the Phase 2 part of the study.
  • Once the recommended Phase 2 dose has been identified, TK-8001 will then be evaluated in an expansion part of the trial.

CDR-Life Announces Appointment of Swethajit Biswas, MD, as Chief Medical Officer

Retrieved on: 
Tuesday, August 23, 2022
Partnership, University, Royal college, Cancer, F.X. v The Clinical Director of Central Mental Hospital and Another, FRCP, National Health Service, Time, Doctor of Philosophy, Multiple myeloma, Severe cognitive impairment, GSK, Royal College of Physicians, Geographic atrophy, LinkedIn, Newcastle, MHC, Antigen, NHS, BCMA, GlaxoSmithKline, Brain, GLOBE, Company, Biotechnology, Therapy, Twitter, Boehringer Ingelheim, Cancer/testis antigens, Sarcoma, Oncology, TCR, Patient, Lymphoma, Fine chemical, Pharmaceutical industry, MD

Prior to joining CDR-Life, Dr. Biswas was a Development Leader for MAGE-A4+ autologous cell therapies at Adaptimmune Therapeutics plc, progressing afamitresgene autoleucel through an accelerated approval submission pathway.

Key Points: 
  • Prior to joining CDR-Life, Dr. Biswas was a Development Leader for MAGE-A4+ autologous cell therapies at Adaptimmune Therapeutics plc, progressing afamitresgene autoleucel through an accelerated approval submission pathway.
  • He also held an academic position as a Clinical Senior Lecturer in medical oncology at Newcastle Universitys Northern Institute for Cancer Research (NICR) from 2009 to 2013.
  • Dr. Biswas received his medical degree from Sheffield University Medical School and his DPhil from the University of Oxford.
  • For more information, please visit cdr-life.com and follow the Company on Twitter and LinkedIn.

T-knife Therapeutics Announces New TCR-T Program Targeting KRAS G12V and Presents Data at the American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Friday, April 8, 2022
Differentiable function, Cancer, Therapy, Epitope, TCR, Cell death, Molecular medicine, Patient, Oncogene, KRAS, Mouse, AACR, Hlas, American Association, Neoplasm, Allele, Cancer/testis antigens, Berlin, Association, American Association for Cancer Research, Technology, Annual general meeting, GLOBE, Toxic shock syndrome toxin, HLA, CD8, Max, SAN, Maintenance, Peptide, Toxicity, Immunization, Vaccine

This is an eventful year for T-knife, filled with meaningful corporate milestones, stated Thomas M. Soloway, Chief Executive Officer of T-knife.

Key Points: 
  • This is an eventful year for T-knife, filled with meaningful corporate milestones, stated Thomas M. Soloway, Chief Executive Officer of T-knife.
  • These TCRs mediated recognition of a large panel of KRASG12V-expressing cancer cell lines, as demonstrated by cytokine responses and cytotoxicity.
  • KRAS mutations are defined as driver mutations, meaning they are responsible for both the initiation and maintenance of cancer.
  • Targeting driver mutations reduces the potential for the tumor to employ immune escape mechanisms, making the KRAS family an ideal target for TCR-T therapy.

Lyell Immunopharma Announces FDA Clearance of IND for LYL132, a T-Cell Receptor Therapy for Solid Tumors Being Developed in Collaboration with GSK

Retrieved on: 
Monday, January 24, 2022
ACT, Board, Survival, Melanoma, Patient, Liver cancer, SAN, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Board of directors, SS, Cancer, Metastasis, Adult, GLOBE, IND, Sarcoma, Tissue, GSK, Bladder cancer, CAR, Cancer/testis antigens, NY-ESO-1, MD, CTA, Food, FDA, TCR, Investigational New Drug, Large-cell lung carcinoma, Pharmaceutical industry, Lyell

The cell surface antigen NY-ESO-1 is a clinically validated target present on many aggressive solid tumors.

Key Points: 
  • The cell surface antigen NY-ESO-1 is a clinically validated target present on many aggressive solid tumors.
  • Clearance of the second IND incorporating Lyells novel reprogramming technologies is another important milestone for Lyell, especially coming within a month of FDA clearance of an IND for LYL797, our lead CAR program, said Liz Homans, Chief Executive Officer of Lyell.
  • Lyell will manufacture LYL132 in its LyFE Manufacturing Center and GSK will conduct the Phase 1 trial.
  • Lyell is a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors.

T-knife Therapeutics Appoints Ronald Krasnow, J.D., as General Counsel

Retrieved on: 
Wednesday, January 5, 2022
University, Therapy, Metallurgy, Acquisition, University of Michigan, General counsel, Patient, Cancer, Hyperkalemia, TCR, Intellectual property, George Washington University Law School, IPO, Senior, FDA, Compliance, Patent, SAN, GLOBE, Patiromer, Technology, Fish, Cancer/testis antigens, Berlin, Molecular medicine, Symyx Technologies, Pharmaceutical industry, Vaccine

SAN FRANCISCO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer, today announced the appointment of Ronald Krasnow, J.D., who brings over thirty years of legal counsel and executive management experience to T-knife.

Key Points: 
  • SAN FRANCISCO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer, today announced the appointment of Ronald Krasnow, J.D., who brings over thirty years of legal counsel and executive management experience to T-knife.
  • I am pleased to welcome Ron to the senior leadership team at T-knife, stated Thomas M. Soloway, Chief Executive Officer of T-knife.
  • Mr. Krasnow was most recently the Chief Operating Officer of Arch Oncology, a company dedicated to antibody therapies for the treatment of cancer.
  • Previously, he was General Counsel, Secretary and Chief Compliance Officer at Menlo Therapeutics.

Global Synovial Sarcoma Pipeline Landscape, 2021 with Insights on 14+ Key Players and Drugs Including ADP-A2M4 (Adaptimmune) and Catequentinib (Advenchen Labs) - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 16, 2021
Health, Pharmaceutical, Clinical trial, Synovial sarcoma, A4, Acquisition, Mergers and acquisitions, Therapy, Discovery, Cancer/testis antigens, MAGE, News, II, Pharmaceutical industry, Synovial

This report provides comprehensive insights about 14+ companies and 14+ pipeline drugs in Synovial sarcoma pipeline landscape.

Key Points: 
  • This report provides comprehensive insights about 14+ companies and 14+ pipeline drugs in Synovial sarcoma pipeline landscape.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Synovial sarcoma R&D.
  • This segment of the Synovial sarcoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery.
  • It also analyses Synovial sarcoma therapeutic drugs key players involved in developing key drugs.

T-knife Therapeutics Appoints Biotech Industry Veteran Laura Brege to its Board of Directors

Retrieved on: 
Tuesday, November 30, 2021
Patient, TCR, Senior advisor, The Cooper Companies, Technology, Industry, Cancer, Amgen, SAN, University, Onyx, Cancer/testis antigens, Therapy, Flex (company), Onyx Pharmaceuticals, GLOBE, Biotechnology, MAGE-A1, Berlin, Board, Ohio University, Treasurer, Chicago (franchise), Molecular medicine, Management, Vaccine

SAN FRANCISCO, Calif., Nov. 30, 2021 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer, today announced that biotech industry veteran Laura Brege has been appointed to the companys Board of Directors.

Key Points: 
  • SAN FRANCISCO, Calif., Nov. 30, 2021 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer, today announced that biotech industry veteran Laura Brege has been appointed to the companys Board of Directors.
  • We are excited to welcome Laura to our Board, stated Thomas M. Soloway, chief executive officer of T-knife.
  • Lauras deep experience spans C-suite positions at multiple biotech companies, senior advisory and board roles and tenure as a venture capital investor.
  • From 2012 to 2015, Ms. Brege served as Chief Executive Officer and President of Nodality, Inc., a privately held biotechnology company focused on oncology and immunology.

T-knife Therapeutics Reports Preclinical Efficacy Data Induced by TK-8001, a Novel MAGE-A1-Specific TCR-T

Retrieved on: 
Monday, November 15, 2021
Safety, Testicle, SITC, Molecular medicine, Cancer, Â, Therapy, Berlin, TCR, Cancer/testis antigens, SAN, Central tolerance, Technology, MAGE-A1, Program, Human, GLOBE, Primary tumor, CD8, Patient, Peptide, Vaccine, Pharmaceutical industry

SAN FRANCISCO, Nov. 15, 2021 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer, reported preclinical data demonstrating that its novel MAGE-A1-specific T cell receptor (TCR) induced meaningful anti-tumor activity and enhanced engraftment as compared to human donor derived TCRs. In vivo data presented at the SITC annual meeting highlight the potential of T-knife’s lead product candidate TK-8001, a TCR engineered T cell therapy (TCR-T) that is being developed to treat MAGE-A1 positive solid tumors. The company plans to initiate a first-in-human, Phase 1/2 trial in early 2022.

Key Points: 
  • T-knife has used its proprietary HuTCR platform to discover multiple naturally optimized high-affinity TCRs specific for the cancer-testis antigen MAGE-A1.
  • These MAGE-A1-specific TCRs were isolated from the HuTCR platform and in vitro and in vivo activity were compared to different human-derived MAGE-A1-specific TCRs.
  • The data generated in these preclinical evaluations highlight the potential therapeutic benefit of TK-8001.
  • It is gratifying for our R&D team to present this exciting preclinical efficacy data in solid tumors expressing MAGE-A1, said Elisa Kieback, Ph.D., founder and Chief Technical Officer of T-knife Therapeutics.